Mergers & Acquisitions
Greenhill's M&A practice includes some of the most experienced professionals in the industry. Drawing on that experience, we are active across the full range of M&A advisory roles:
Sell-side Advisory
Leveraging our network of experienced Managing Directors, we have a strong track record in sell side advisory roles. Acting for target companies, special board committees or selling shareholders, we can operate at the heart of any process, assist in negotiations and provide incisive and deeply informed advice about the merits of bids received.
Buy-side Advisory
We have a strong record of successful buy side advisory assignments in relation to public or private target companies and are able to advise interested buyers on attractive targets through our global network of relationships.
Merger Advisory
Greenhill is well qualified to assist clients on merger transactions given the long experience of its partners and professionals, an assurance of total discretion. Greenhill has a number of sizeable mergers in its list of completed transactions both in the US and internationally.
Special Advisory
Various advisory work that we undertake does not fit a conventional ‘transaction’ definition. Examples include our work advising the Australian National Rugby League Commission on the sale of television broadcast rights and work for the global partnership of Arthur Andersen in the immediate aftermath of the cases that followed the collapse of Enron. We believe that Greenhill’s experience, expertise and discretion positions us well for special advisory assignments.
Cross-border Advisory
Greenhill’s network of international offices allow us to offer clients a seamless cross-border advisory service with a truly global perspective.
Recent Transactions
Sort By
Clinigen Ltd’s portfolio of Established Medicines
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
Farmalider Group
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
Synfonium / Qwant / Shadow
Advised Banque des Territoires / Groupe Caisse des Dépôts (CDC), a French Public Institution, on the investment in the newly created platform Synfonium, incorporating Shadow, a cloud-based platform, and Qwant, a sovereign search engine. CDC will hold a 25% stake in Synfonium, while Octave Klaba and Miroslaw Klaba, the co-founders of OVHcloud, will hold the remaining 75%
Distribuidora Internacional Carmen SAU
Advised Diploma PLC in the acquisition of Distribuidora Internacional Carmen SAU (“DICSA”), a market-leading distributor of fluid power solutions into the European aftermarket
Australian Unity Diversified Property Fund
Advising Australian Unity Property Limited, as the responsible entity of the Australian Unity Diversified Property Fund, on Australian Unity Diversified Property Fund’s merger with Cromwell Direct Property Fund